SPATA31D2P

Across TCGA pan-cancer cohorts, SPATA31D2P RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated SPATA31D2P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SPATA31D2P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SPATA31D2P expression acts as an unfavorable survival marker, although some lineages such as LUSC and STAD show a favorable association.

LIHC, DLBC, and PAAD are the cancer types where SPATA31D2P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.121	0.627	<.001	27	view →
DLBC	DFS	Tertile	II,III,IV	0.357	0.876	.010	21	view →
PAAD	OS	Tertile	All	0.132	0.590	<.001	18	view →
THCA	DFS	Tertile	IV	0.126	0.805	.002	18	view →
LUSC	DFS	Tertile	III,IV	1.000	0.333	.018	12	view →
ESCA	OS	Tertile	All	0.598	0.895	.043	9	view →
STAD	DFS	Quartile	III,IV	0.792	0.525	.024	8	view →
LGG	DFS	Tertile	All	0.667	0.835	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SPATA31D2P–LIHC (OS)

Open the LIHC breakdown →